Ovid Therapeutics $OVID Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. raised its position in Ovid Therapeutics (NASDAQ:OVID) by 112.2% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 924,576 shares of the company’s stock after buying an additional 488,956 shares during the quarter. Assenagon Asset Management S.A.’s holdings in Ovid Therapeutics were worth $1,202,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Bank of America Corp DE raised its position in Ovid Therapeutics by 49.7% during the 4th quarter. Bank of America Corp DE now owns 56,733 shares of the company’s stock worth $53,000 after buying an additional 18,841 shares during the last quarter. Velan Capital Investment Management LP grew its position in shares of Ovid Therapeutics by 64.9% in the second quarter. Velan Capital Investment Management LP now owns 160,000 shares of the company’s stock valued at $53,000 after purchasing an additional 63,000 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Ovid Therapeutics in the first quarter valued at $37,000. Jane Street Group LLC purchased a new stake in Ovid Therapeutics in the 2nd quarter worth approximately $47,000. Finally, Adage Capital Partners GP L.L.C. boosted its stake in Ovid Therapeutics by 15.0% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 1,150,000 shares of the company’s stock worth $359,000 after buying an additional 150,000 shares during the last quarter. 72.24% of the stock is owned by institutional investors and hedge funds.

Ovid Therapeutics Stock Performance

OVID opened at $1.79 on Thursday. Ovid Therapeutics has a 52-week low of $0.24 and a 52-week high of $2.01. The company has a market cap of $127.11 million, a PE ratio of -3.57 and a beta of 0.04. The company has a debt-to-equity ratio of 0.28, a quick ratio of 4.24 and a current ratio of 4.24. The stock has a 50-day moving average of $1.51 and a 200-day moving average of $1.09.

Ovid Therapeutics (NASDAQ:OVID) last posted its quarterly earnings data on Wednesday, November 12th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.02). Ovid Therapeutics had a negative return on equity of 63.79% and a negative net margin of 550.04%.The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.17 million. As a group, equities research analysts forecast that Ovid Therapeutics will post -0.4 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have commented on OVID. Roth Capital began coverage on Ovid Therapeutics in a research note on Thursday, December 11th. They set a “buy” rating and a $3.00 price target for the company. Leerink Partnrs upgraded Ovid Therapeutics to a “strong-buy” rating in a research note on Monday, November 17th. Leerink Partners started coverage on shares of Ovid Therapeutics in a research report on Monday, November 17th. They set an “outperform” rating and a $5.00 price target for the company. Wall Street Zen lowered shares of Ovid Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, November 15th. Finally, HC Wainwright reiterated a “buy” rating and issued a $2.00 price target on shares of Ovid Therapeutics in a research report on Monday. Two equities research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $3.88.

Key Stores Impacting Ovid Therapeutics

Here are the key news stories impacting Ovid Therapeutics this week:

• Positive Sentiment: LifeSci Capital initiated coverage with an “Outperform” rating and a $4.00 price target, publishing detailed quarterly and FY EPS forecasts that show improving (but still negative) losses through FY2026 — this institutional initiation and multi-quarter model give the stock a visible analyst catalyst. LifeSci Capital initiates coverage of Ovid Therapeutics (OVID) with outperform recommendation
• Positive Sentiment: HC Wainwright & Co. reiterated a buy recommendation, reinforcing sell-side support that could help sustain investor interest and trading momentum. HC Wainwright & Co. reiterates Ovid Therapeutics (OVID) buy recommendation
• Neutral Sentiment: LifeSci’s published model projects ongoing negative EPS (examples: FY2025 ~($0.46), FY2026 ~($0.38), quarterly EPS in the ~$0.08–$0.11 loss range) — the estimates provide a roadmap for expected cash burn and timing for any positive financial inflection, but they are not evidence of immediate revenue improvement.
• Neutral Sentiment: A December short-interest report shows an apparent large “increase” but lists zero shares and a 0.0 days-to-cover figure — this looks like a data glitch and shouldn’t be treated as a meaningful change in sentiment until corrected or clarified by exchanges/brokers.

About Ovid Therapeutics

Ovid Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapies for rare neurological disorders. Founded in 2014 and headquartered in New York, the company applies a precision medicine approach to target underlying mechanisms of disease in patients with genetic conditions affecting the central nervous system. Its research platform centers on small-molecule modulators of neurotransmitter pathways to restore neural network function in disorders with high unmet medical need.

The company’s lead development candidate, OV101 (gaboxadol), is a selective extrasynaptic GABAA receptor agonist being investigated for the treatment of Angelman syndrome and Fragile X syndrome.